Century Therapeutics 2025 Q1 Earnings 372.8% Net Income Surge Amidst 12,667.7% Revenue Jump

Century Therapeutics (IPSC) reported a stunning fiscal 2025 Q1 performance on Nov 14, 2025, marked by a 12,667.7% revenue surge and a record $76.56 million net income. Despite these gains, the stock has declined sharply in the post-earnings period, raising questions about market reception.

Revenue

Total revenue for Century Therapeutics soared to $109.16 million in Q1 2025, a staggering increase from $855,000 in the same period the previous year. This growth was entirely driven by collaboration revenue, which accounted for the full $109.16 million in reported income. The 12,667.7% year-over-year jump reflects a one-time milestone in partnership monetization, signaling a pivotal shift in the company’s revenue model.

Earnings/Net Income

The company returned to profitability with an EPS of $0.89 in Q1 2025, reversing a $0.45 loss in Q1 2024—a 297.8% improvement. Net income reached $76.56 million, a 372.8% positive swing from a $28.06 million net loss in the prior year. This marked the highest Q1 net income in four years, underscoring a strategic and operational turnaround. The EPS improvement is a strong indicator of the company’s ability to convert collaboration-driven revenue into profitability.

Post-Earnings Price Action Review

The strategy of buying IPSC shares on revenue raise announcements and holding for 30 days has shown mixed results over the past three years. A backtest revealed 2 positive days and 14 negative days, with most losses occurring shortly after the announcements. The cumulative return for the 30-day period was -14.5%, highlighting short-term underperformance. Immediate post-announcement months saw an average loss of -7.5%, though some recovery occurred in later months. Comparisons with the NASDAQ Composite Index revealed IPSC’s heightened volatility, suggesting the strategy lags behind broader market stability.

CEO Commentary

Century Therapeutics’ CEO, Brent Pfeiffenberger, emphasized the Q1 results as a “transformative milestone,” attributing the revenue surge to the termination of the Bristol-Myers Squibb collaboration. He highlighted the company’s focus on advancing CNTY-813, its Type 1 diabetes beta islet program, and CNTY-308, an autoimmune cell therapy candidate. “Our cash runway into 4Q 2027 provides flexibility to execute IND-enabling studies and pursue regulatory milestones,” Pfeiffenberger stated, underscoring confidence in the pipeline’s potential to drive long-term value.

Additional News

1. New Beta Islet Program for T1D: Century announced CNTY-813, leveraging Allo-Evasion™ 5.0-engineered iPSC beta islets to address immune rejection. Preclinical data showed rapid diabetes reversal in mouse models, with IND-enabling studies slated for late 2025.

2. Q3 2025 Financial Update: The company reported a $34.4 million net loss for Q3, driven by $22.5 million in R&D expenses. Cash reserves stood at $132.7 million, with a projected runway through 4Q 2027.

3. Strategic Cost Reductions: A 51% workforce reduction in July 2025 streamlined operations, aligning with a focus on high-potential programs like CNTY-813 and CNTY-308.